ArticleBMC cardiovascular disorders2025
The relationship between Non-HDL/HDL ratio and in-stent restenosis in patients with coronary artery atherosclerosis after percutaneous coronary intervention.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough percutaneous coronary intervention (PCI) is an effective treatment for coronary artery disease (CAD). However, the occurrence of in-stent restenosis (ISR) remains a critical issue in clinical practice. The non-high-density lipoprotein cholesterol (non-HDL) to high-density lipoprotein cholesterol (HDL) ratio (NHHR) is a novel lipid parameter that has been linked to various cardiovascular disorders. Nevertheless, its relationship with ISR after drug-eluting stent implantation remains to be elucidated. This study aims to explore the association between NHHR and ISR, evaluate its predictive value for ISR, and compare it with other lipid parameters.
methodsThis retrospective study included 594 CAD patients who underwent coronary angiography follow-up after surgery. Patients were divided into the ISR group (182 cases, 30.64%) and the non-ISR group (412 cases, 69.36%). Laboratory parameters of patients were measured and collected. Subsequently, both univariate and multivariate logistic regression models were used to identify the relevant influencing factors of ISR. The association between the NHHR and ISR was analyzed by restricted cubic splines regression, and the potential risk threshold preliminarily estimated. Receiver operating characteristic (ROC) curve analysis was used to evaluate the predictive value of NHHR for ISR.
resultsIn the multivariate logistic regression models, the NHHR was significantly associated with the risk of ISR (max odds ratio = 1.806, P < 0.05 in all models). ROC curve analysis showed that the area under the curve for NHHR predicting ISR was 0.692 (95% Confidence Interval: 0.646-0.737), which was superior to those observed for low-density lipoprotein cholesterol (0.592, 95% Confidence Interval: 0.542-0.642), high-density lipoprotein cholesterol (0.407, 95% Confidence Interval: 0.358-0.456), triglyceride (0.58, 95% Confidence Interval: 0.531-0.629), total cholesterol (0.625, 95% Confidence Interval: 0.575-0.675), non-HDL (0.659, 95% Confidence Interval: 0.612-0.707), and LDL/HDL (0.634, 95% Confidence Interval: 0.585-0.682) (P < 0.001), indicating that NHHR has a relatively good predictive effect on ISR. The non-linear regression analysis results indicate that there is a nonlinear relationship and the risk of ISR occurrence increases with the increase of NHHR.
conclusionThe NHHR is independently associated with the risk of ISR after drug-eluting stent implantation in patients with CAD and exhibits a superior predictive capacity for ISR compared to other lipid parameters.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.